ATE541047T1 - Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen - Google Patents

Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen

Info

Publication number
ATE541047T1
ATE541047T1 AT03816723T AT03816723T ATE541047T1 AT E541047 T1 ATE541047 T1 AT E541047T1 AT 03816723 T AT03816723 T AT 03816723T AT 03816723 T AT03816723 T AT 03816723T AT E541047 T1 ATE541047 T1 AT E541047T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
therapeutic monoclonal
botulinum neurotoxins
antibodies
neutralizing
Prior art date
Application number
AT03816723T
Other languages
English (en)
Inventor
James Marks
Peter Amersdorfer
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE541047T1 publication Critical patent/ATE541047T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03816723T 2002-08-01 2003-08-01 Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen ATE541047T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40072102P 2002-08-01 2002-08-01
PCT/US2003/024371 WO2005016232A2 (en) 2002-08-01 2003-08-01 Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

Publications (1)

Publication Number Publication Date
ATE541047T1 true ATE541047T1 (de) 2012-01-15

Family

ID=34192937

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03816723T ATE541047T1 (de) 2002-08-01 2003-08-01 Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen

Country Status (5)

Country Link
EP (2) EP1572121B1 (de)
AT (1) ATE541047T1 (de)
AU (1) AU2003304411A1 (de)
CA (1) CA2492883C (de)
WO (1) WO2005016232A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
AU2006332045A1 (en) 2005-01-27 2007-08-16 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2009008916A2 (en) 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US8540987B2 (en) 2008-01-29 2013-09-24 Institute For Antibodies Co., Ltd. Composition for neutralizing botulinus toxin type-A, and human anti-botulinus toxin type-A antibody
KR101806567B1 (ko) 2009-02-19 2018-01-10 메르츠 파마 게엠베하 운트 코. 카가아 매우 순수한 신경독을 제조하기 위한 수단 및 방법
NL2002868C2 (en) * 2009-05-11 2010-11-15 Ibis Technologies B V Method for the determination of competing interactants binding to a compound, use, combination and apparatus.
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
CA2880897C (en) * 2012-11-21 2020-01-14 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
US20240307338A1 (en) * 2021-01-27 2024-09-19 Sichuan Jiuzhang Biological Science And Technology Co., Ltd. Use of pharmaceutical composition containing chlorogenic acid in preparation of medicament for treating pathologic jaundice

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254082A (en) 1978-06-12 1981-03-03 Miles Laboratories, Inc. Specific binding-adsorbent assay test means
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
JPS58215453A (ja) 1982-06-09 1983-12-14 Toray Silicone Co Ltd 室温硬化後塗装可能なオルガノポリシロキサン組成物
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL84285A (en) 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5001065A (en) 1987-05-27 1991-03-19 Cetus Corporation Human cell line and triomas, antibodies, and transformants derived therefrom
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5231026A (en) 1987-12-31 1993-07-27 Tanox Biosystems, Inc. DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US5292867A (en) 1988-11-16 1994-03-08 Tanox Biosystems, Inc. Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin
IL94872A (en) 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies reactive with human carcinomas, recombinant proteins comprising their antigen binding region, pharmaceutical compositions and kits comprising said antibodies and methods for imaging human carcinoma using same
US5081235A (en) 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
US5075431A (en) 1989-07-26 1991-12-24 City Of Hope Chimeric anti-CEA antibody
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5472693A (en) 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
US5506132A (en) 1993-07-28 1996-04-09 Sandoz Pharmaceuticals Corporation Human antibodies against varicella-zoster virus
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
US5691447A (en) 1995-03-24 1997-11-25 Tanox Biosystems, Inc. GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20020155114A1 (en) * 1998-08-31 2002-10-24 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US6667158B1 (en) * 1998-12-17 2003-12-23 The United States Of America As Represented By The Secretary Of The Army Antibodies against type a botulinum neurotoxin
WO2005030119A2 (en) * 2003-04-11 2005-04-07 Allergan, Inc. Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية

Also Published As

Publication number Publication date
WO2005016232A3 (en) 2005-09-15
EP2436774A2 (de) 2012-04-04
EP1572121B1 (de) 2012-01-11
EP1572121A2 (de) 2005-09-14
AU2003304411A8 (en) 2005-03-07
AU2003304411A1 (en) 2005-03-07
WO2005016232A2 (en) 2005-02-24
EP1572121A4 (de) 2007-11-07
CA2492883C (en) 2012-10-02
EP2436774A3 (de) 2012-06-13
CA2492883A1 (en) 2005-02-01

Similar Documents

Publication Publication Date Title
WO2007094754A3 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2010014854A3 (en) Antibodies that neutralize botulinum neurotoxins
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
PT1766093E (pt) Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
NO20074563L (no) Novel anti-plgf antibody
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
ATE520416T1 (de) Menschliche anti-ifn-gamma-neutralisierende antikörper als selektive inhibitoren des ifn- gamma-wegs
DE60005953D1 (de) Stapelbare statische mischelemente
PT1639011E (pt) Anticorpos (dab) de domínio único peguilados
ATE545657T1 (de) Tgf-beta antikörper
ATE541047T1 (de) Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
EA200701452A1 (ru) Моноклональные антитела против подобного ангиопоэтину белка 4 (angptl 4)
EP1411962A4 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
BR0315042A (pt) Terapia para o tratamento de aterosclerose baseada em imunização passiva por peptìdeo
GB0324656D0 (en) A protein involved in ovarian cancer